Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA approves Olumiant as first systemic therapy for baldness form 

By Brian Buntz | June 13, 2022

Eli Lilly in the Drug Discovery & Development Pharma 50The FDA has announced that it has approved Lilly’s Olumiant (baricitinib) oral tablets to treat adults with severe alopecia areata, a form of baldness resulting from the body attacking its hair follicles.

Manifesting as patchy baldness, alopecia areata affects more than 300,000 people in the U.S.

The incidence of alopecia areata is growing.

“Access to safe and effective treatment options is crucial for the significant number of Americans affected by severe alopecia,” said Dr. Kendall Marcus, director of the division of dermatology and dentistry in the FDA’s Center for Drug Evaluation and Research, in a news release. “Today’s approval will help fulfill a significant unmet need for patients with severe alopecia areata.”

FDA first approved Olumiant in 2018 for rheumatoid arthritis. In 2022, the drug won an indication for COVID-19 in some hospitalized COVID-19 patients.

Olumiant

Image courtesy of Lilly

Baricitinib is an ​​oral JAK inhibitor.

Researchers have also successfully used another JAK inhibitor, Xeljanz (tofacitinib) from Pfizer (NYSE:PFE), to treat severe alopecia areata. In May, NEJM published a summary of Phase 3 studies of baricitinib for alopecia areata.

In 2021, Olumiant sales were $1.115 billion, marking a 59% increase over the prior year.

To win approval for alopecia areata, Lilly included Olumiant in two randomized, double-blind, placebo-controlled studies known as Trial AA-1 and Trial AA-2.

Volunteers in the study had at least 50% scalp hair loss and received either a daily placebo or 2- or 4-mg of Olumiant.

The study’s primary endpoint was at least 80% scalp hair coverage at week 36.

Approximately one-third of recipients of 4 mg of Olumiant achieved adequate scalp hair coverage in the studies.

After one year, approximately half of the patients had substantial hair regrowth.

In addition to Pfizer, Concert Pharmaceuticals is also developing a JAK inhibitor for alopecia areata.


Filed Under: clinical trials, Dermatology, Drug Discovery
Tagged With: baricitinib, Eli Lilly, FDA, Olumiant, tofacitinib, Xeljanz
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Takeda
TAK-279, an oral small-molecule TYK2 inhibitor offering the convenience of a once-daily pill and biologic-like clinical responses
AbbVie 770 logo
Upadacitinib shows promising results in ongoing phase 3 atopic dermatitis studies
plant under a microscope
Legacy Healthcare aims to upend alopecia areata treatment with a botanical drug
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE